{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:19:21Z","timestamp":1789129161040,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.diabres.2011.09.027","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T09:28:56Z","timestamp":1319707736000},"page":"389-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers"],"prefix":"10.1016","volume":"95","author":[{"given":"Xanthia F.","family":"Samaropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laney","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter T.","family":"Ambrosius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M.","family":"Marcovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Probstfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C. Goff","family":"Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12A","key":"10.1016\/j.diabres.2011.09.027_bib0005","doi-asserted-by":"crossref","first-page":"4i","DOI":"10.1016\/j.amjcard.2007.03.002","article-title":"Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial","volume":"99","author":"Goff","year":"2007","journal-title":"Am J Cardio"},{"issue":"3","key":"10.1016\/j.diabres.2011.09.027_bib0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.diabres.2011.09.027_bib0015","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2011.09.027_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/0003-4819-145-1-200607040-00129","article-title":"Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease","volume":"145","author":"Lloyd-Jones","year":"2006","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2011.09.027_bib0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1559-4564.2006.05538.x","article-title":"Interrelationships between inflammation, C-reactive protein, and insulin resistance","volume":"1","author":"Ndumele","year":"2006","journal-title":"J Cardiometab Syndr"},{"issue":"9","key":"10.1016\/j.diabres.2011.09.027_bib0030","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2008-2534","article-title":"Cytokine and cytokine-like inflammation markers: endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications","volume":"94","author":"Goldberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2011.09.027_bib0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MAJ.0b013e3181a4158c","article-title":"Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts","volume":"338","author":"Rizvi","year":"2009","journal-title":"Am J Med Sci"},{"issue":"2A","key":"10.1016\/j.diabres.2011.09.027_bib0040","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/j.amjcard.2005.11.010","article-title":"The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease","volume":"97","author":"Haffner","year":"2006","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.diabres.2011.09.027_bib0045","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1155\/2009\/703927","article-title":"Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus","volume":"27","author":"Swellam","year":"2009","journal-title":"Dis Markers"},{"issue":"6","key":"10.1016\/j.diabres.2011.09.027_bib0050","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jamcollsurg.2008.08.022","article-title":"Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004","volume":"207","author":"Nguyen","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.diabres.2011.09.027_bib0055","first-page":"7","article-title":"Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment","volume":"22","author":"Farah","year":"2008","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2011.09.027_bib0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02693938","article-title":"Statins and biomarkers of inflammation","volume":"9","author":"Devaraj","year":"2007","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"10.1016\/j.diabres.2011.09.027_bib0065","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2009.1347","article-title":"Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes. The LANCET Randomized Trial","volume":"302","author":"Pradhan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2011.09.027_bib0070","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/01.CIR.0000165064.31505.3B","article-title":"Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial","volume":"111","author":"Schaumberg","year":"2005","journal-title":"Circulation"},{"issue":"12A","key":"10.1016\/j.diabres.2011.09.027_bib0075","first-page":"21i","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods","volume":"99","author":"The ACCORD Study Group","year":"2007","journal-title":"Am J Cardio"},{"issue":"12A","key":"10.1016\/j.diabres.2011.09.027_bib0080","doi-asserted-by":"crossref","first-page":"34i","DOI":"10.1016\/j.amjcard.2007.03.004","article-title":"Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial","volume":"99","author":"Gerstein","year":"2007","journal-title":"Am J Cardio"},{"issue":"12A","key":"10.1016\/j.diabres.2011.09.027_bib0085","doi-asserted-by":"crossref","first-page":"44i","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial","volume":"99","author":"Cushman","year":"2007","journal-title":"Am J Cardio"},{"issue":"12A","key":"10.1016\/j.diabres.2011.09.027_bib0090","doi-asserted-by":"crossref","first-page":"56i","DOI":"10.1016\/j.amjcard.2007.03.024","article-title":"Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial","volume":"99","author":"Ginsberg","year":"2007","journal-title":"Am J Cardio"},{"issue":"24","key":"10.1016\/j.diabres.2011.09.027_bib0095","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.diabres.2011.09.027_bib0100","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood pressure control in type 2 diabetes Mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.diabres.2011.09.027_bib0105","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"issue":"9739","key":"10.1016\/j.diabres.2011.09.027_bib0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.diabres.2011.09.027_bib0115","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"ACORD Study Group","year":"2011","journal-title":"N Engl J Med"},{"issue":"12A","key":"10.1016\/j.diabres.2011.09.027_bib0120","doi-asserted-by":"crossref","first-page":"112i","DOI":"10.1016\/j.amjcard.2007.03.029","article-title":"The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods","volume":"99","author":"Williamson","year":"2007","journal-title":"Am J Cardio"},{"issue":"2","key":"10.1016\/j.diabres.2011.09.027_bib0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/dc08-1153","volume":"32","author":"Cukierman-Yaffe","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2011.09.027_bib0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2310\/6650.2005.05012","article-title":"Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus","volume":"54","author":"Aviles-Santa","year":"2006","journal-title":"J Investig Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822711005298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822711005298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:04:50Z","timestamp":1759172690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822711005298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0168822711005298"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2011.09.027","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2011.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}